Efficacy and safety of gluten peptide-based antigen-specific immunotherapy (Nexvax2) in adults with coeliac disease after bolus exposure to gluten (RESET CeD): an interim analysis of a terminated randomised, double-blind, placebo-controlled phase 2 study

Anderson, 2022, Emergence of an adaptive immune paradigm to explain celiac disease: a perspective on new evidence and implications for future interventions and diagnosis, Expert Rev Clin Immunol, 18, 75, 10.1080/1744666X.2021.2006636 Leffler, 2015, Larazotide acetate for persistent symptoms of celiac disease despite a gluten-free diet: a randomized controlled trial, Gastroenterology, 148, 1311, 10.1053/j.gastro.2015.02.008 Murray, 2017, No difference between latiglutenase and placebo in reducing villous atrophy or improving symptoms in patients with symptomatic celiac disease, Gastroenterology, 152, 787, 10.1053/j.gastro.2016.11.004 Schuppan, 2021, A randomized trial of a transglutaminase 2 inhibitor for celiac disease, N Engl J Med, 385, 35, 10.1056/NEJMoa2032441 2022, FDA draft guidance for developing drugs for adjunctive treatment to a gluten-free diet: comments by the society for the study of celiac disease, Gastroenterology Goel, 2019, Cytokine release and gastrointestinal symptoms after gluten challenge in celiac disease, Sci Adv, 5, 10.1126/sciadv.aaw7756 Goel, 2017, Epitope-specific immunotherapy targeting CD4-positive T cells in coeliac disease: two randomised, double-blind, placebo-controlled phase 1 studies, Lancet Gastroenterol Hepatol, 2, 479, 10.1016/S2468-1253(17)30110-3 Anderson, 2013, Vaccine against autoimmune disease: antigen-specific immunotherapy, Curr Opin Immunol, 25, 410, 10.1016/j.coi.2013.02.004 Medawar, 1961, Immunological tolerance, Science, 133, 303, 10.1126/science.133.3449.303 Larché, 2005, Peptide-based therapeutic vaccines for allergic and autoimmune diseases, Nat Med, 11, S69, 10.1038/nm1226 Tye-Din, 2010, Comprehensive, quantitative mapping of T cell epitopes in gluten in celiac disease, Sci Transl Med, 2, 10.1126/scitranslmed.3001012 Truitt, 2019, Randomised clinical trial: a placebo-controlled study of subcutaneous or intradermal NEXVAX2, an investigational immunomodulatory peptide therapy for coeliac disease, Aliment Pharmacol Ther, 50, 547, 10.1111/apt.15435 Goel, 2020, Serum cytokines elevated during gluten-mediated cytokine release in coeliac disease, Clin Exp Immunol, 199, 68, 10.1111/cei.13369 Daveson, 2017, EBioMedicine, 26, 78, 10.1016/j.ebiom.2017.11.018 Bruins, 2013, The clinical response to gluten challenge: a review of the literature, Nutrients, 5, 4614, 10.3390/nu5114614 Daveson, 2020, Baseline quantitative histology in therapeutics trials reveals villus atrophy in most patients with coeliac disease who appear well controlled on gluten-free diet, GastroHep, 2, 22, 10.1002/ygh2.380 Tye-Din, 2020, Patient factors influencing acute gluten reactions and cytokine release in treated coeliac disease, BMC Med, 18, 362, 10.1186/s12916-020-01828-y Daveson, 2020, Masked bolus gluten challenge low in FODMAPs implicates nausea and vomiting as key symptoms associated with immune activation in treated coeliac disease, Aliment Pharmacol Ther, 51, 244, 10.1111/apt.15551 Hardy, 2021, A sensitive whole blood assay detects antigen-stimulated cytokine release from CD4+ T cells and facilitates immunomonitoring in a phase 2 clinical trial of nexvax2 in coeliac disease, Front Immunol, 12, 10.3389/fimmu.2021.661622 Tye-Din, 2019, Elevated serum interleukin-2 after gluten correlates with symptoms and is a potential diagnostic biomarker for coeliac disease, Aliment Pharmacol Ther, 50, 901, 10.1111/apt.15477 Kasarda, 2013, Can an increase in celiac disease be attributed to an increase in the gluten content of wheat as a consequence of wheat breeding?, J Agric Food Chem, 61, 1155, 10.1021/jf305122s Taavela, 2013, Validation of morphometric analyses of small-intestinal biopsy readouts in celiac disease, PLoS One, 8, 10.1371/journal.pone.0076163 Anderson, 2021, Whole blood interleukin-2 release test to detect and characterize rare circulating gluten-specific T cell responses in coeliac disease, Clin Exp Immunol, 204, 321, 10.1111/cei.13578 Leffler, 2016, Development of celiac disease therapeutics: report of the third gastroenterology regulatory endpoints and advancement of therapeutics workshop, Gastroenterology, 151, 407, 10.1053/j.gastro.2016.07.025 Clifford, 2020, Concepts and instruments for patient-reported outcome assessment in celiac disease: literature review and experts' perspectives, Value Health, 23, 977, 10.1016/j.jval.2019.07.018 Tye-Din, 2020, Cytokine release after gluten ingestion differentiates coeliac disease from self-reported gluten sensitivity, United European Gastroenterol J, 8, 108, 10.1177/2050640619874173 Leonard, 2021, Evaluating responses to gluten challenge: a randomized, double-blind, 2-dose gluten challenge trial, Gastroenterology, 160, 720, 10.1053/j.gastro.2020.10.040 Cartee, 2021, Plasma IL-2 and symptoms response after acute gluten exposure in subjects with celiac disease or nonceliac gluten sensitivity, Am J Gastroenterol, 117, 319, 10.14309/ajg.0000000000001565 Dotsenko, 2021, Genome-wide transcriptomic analysis of intestinal mucosa in celiac disease patients on a gluten-free diet and postgluten challenge, Cell Mol Gastroenterol Hepatol, 11, 13, 10.1016/j.jcmgh.2020.07.010